Digest Network Come funziona
Network
/
Società
EN
Non verificato

ENYO Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati
02/06/2026
ENYO Pharma Appoints Jeff George as Chairman to Support Next Phase of Growth and Phase 3 Readiness
Fonte
ENYO Pharma
Emittente
Business Wire
1.00
0
08/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
ENYO Pharma Announces Completion and Topline Data From Phase 2 Alpestria-1 Clinical Study in Alport Syndrome Demonstrating Vonafexor Reverses Kidney Function Decline and Has Sustained Therapeutic Benefit
Fonte
ENYO Pharma
Emittente
Business Wire
1.00
0
12/06/2025
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome Patients
Fonte
ENYO Pharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0